Advanced Machine Tool Testing Facility Competitors

Headquartered in New Orleans, Louisiana, for over 80 years, IMTT is an industry leader in the handling and storage of bulk liquid products through its ownership and operation of approximately 41 million barrels of storage capacity across 11 terminals throughout North America. IMTT's terminals handle petroleum, biofuels, commodity/specialty chemicals, and vegetable/tropical oil products for customers including refiners, commodities traders, and chemical manufacturers and distributors. Riverstone Holdings LLC acquired IMTT on December 23, 2020.

ITS supports modern travel and spend programs by bringing business travel, payments, expenses, and event logistics into one connected system. By linking policy, booking, payment, and reconciliation in a single end-to-end workflow, ITS enforces policy at the point of purchase, not after the fact. Finance teams gain real time visibility, procurement gets built in compliance, and employees move faster with an experience they actually use. For airlines and crew based organizations managing high-volume, complex travel, ITS’s automated approach reduces manual coordination, scales exception handling, and keeps programs running smoothly. Unlike fragmented point solutions, ITS helps organizations control spend before it happens, reduce manual work, and manage travel and spend as a governed, scalable program.

Applied Molecular Therapeutics (AMT), a public biopharmaceutical company based in South San Francisco, California, is committed to developing novel, oral biological therapeutics to treat severe autoimmune, metabolic and inflammatory diseases. AMT is leveraging its propriety technology platforms to create gastrointestinal (GI)-select therapeutics that harness naturally occurring transport and targeting mechanisms to cross the protective barrier of the intestinal epithelium (IE). Once across the IE, the therapeutics gain privileged access to the immune cell-rich environment of the GI tissue as well as the hepatic portal system and downstream systemic circulation. With this privileged access, AMT’s goal is to develop transformative new oral therapeutic treatment options that offer patients greater efficacy and tolerability than available with today’s therapeutics. AMT has a robust pipeline of oral biologic product opportunities, including AMT-101 which is currently in Phase 1b clinical development for the treatment of adults with ulcerative colitis (UC). AMT-101 is a novel, gut-selective, investigational oral biologic fusion protein of interleukin 10 (IL-10), an anti-inflammatory cytokine. Derived from AMT’s proprietary platforms, AMT-101 is engineered to cross the selective barrier of the IE and enhance localized IL-10 directly within the immune-cell rich environment of GI tissue where up to 75 percent of immune cells reside. This direct targeting of the immune system creates the potential for AMT-101 to address, at its point of origin, the immune dysregulation that gives rise to UC and other inflammatory bowel diseases, and restore immune homeostasis with minimal systemic exposure and potentially fewer adverse events compared to systemic administration of IL-10. AMT has amassed a broad global IP portfolio surrounding its multiple technology platforms and therapeutic programs.